ArticleThe Pan African medical journal2025
Treatment outcomes among patients with drug-resistant tuberculosis managed with BPaL/BPaLM regimen in the Southeast Zone of Nigeria.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and Safety of Bedaquiline-Containing Modified Shorter Regimens for Multidrug- or Rifampicin-Resistant Tuberculosis: A Single-Arm Meta-Analysis.Pathogens (Basel, Switzerland) · 2026Pooled it
- Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review.IJTLD open · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: the treatment of multidrug-resistant tuberculosis (MDR-TB) has been challenging, often associated with life-threatening adverse events and poor treatment outcomes. The recent World Health Organization (WHO) recommendation of the BPaLM regimen, consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin for treatment of pre-extensively drug-resistant tuberculosis (Pre-XDR) and rifampicin-resistant tuberculosis (MDR-TB/RR), has been shown to have favorable treatment outcomes. This study focused on the outcomes of patients managed with this regimen in the southeastern zone of Nigeria between November 2023 and October 2024, following approval by the National Tuberculosis and Leprosy Control Program (NTBLCP) in November 2023. Methods: patient demographic and clinical data were collected from DR-TB treatment registers, active drug safety monitoring forms (aDSM), and laboratory registers using an abstraction tool. Data were analyzed using descriptive statistics such as frequency and percentages for variables such as age, gender, adverse events, new and retreatment cases, treatment outcomes such as completed treatment, cured, loss to follow-up (LTFU), and death. Results: out of the 212 patients enrolled for treatment during the period, 202 patients were treated for MDR-TB/RR with BPaLM, while 10 were treated for Pre-XDR with BPaL. The TSR for the MDR-TB/RR category is 89%, while the TSR for the Pre-XDR category is 100%. More than 6.7% of the patients in the MDR-TB/RR category were LFTU, and another 6.7% died. Over 86% of the patients treated had no documentation for adverse events, while 54% of the MDR-TB/RR cases were new cases. Conclusion: using the BPaLM regimen for DR-TB treatment results in favorable patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.